KDM1A and acute myeloid leukemia: However, In a phase-I/II clinical trial using the LSD1 inhibitor tranylcypromine (TCP) in combination with all-trans retinoic acid (ATRA) for r/r AML patients, there was an overall response rate of only 20%.